AstraZeneca PLC (NASDAQ:AZN) Shares Purchased by D.B. Root & Company LLC

D.B. Root & Company LLC raised its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 4.0% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,919 shares of the company’s stock after buying an additional 345 shares during the quarter. D.B. Root & Company LLC’s holdings in AstraZeneca were worth $695,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Concurrent Investment Advisors LLC raised its stake in AstraZeneca by 39.6% during the third quarter. Concurrent Investment Advisors LLC now owns 12,685 shares of the company’s stock valued at $988,000 after buying an additional 3,597 shares in the last quarter. Harvest Portfolios Group Inc. grew its holdings in shares of AstraZeneca by 3.0% during the third quarter. Harvest Portfolios Group Inc. now owns 728,187 shares of the company’s stock valued at $56,733,000 after purchasing an additional 21,514 shares during the last quarter. Pittenger & Anderson Inc. grew its holdings in shares of AstraZeneca by 14.1% during the third quarter. Pittenger & Anderson Inc. now owns 53,377 shares of the company’s stock valued at $4,159,000 after purchasing an additional 6,590 shares during the last quarter. Martin Investment Management LLC grew its holdings in shares of AstraZeneca by 2.8% during the third quarter. Martin Investment Management LLC now owns 284,204 shares of the company’s stock valued at $22,571,000 after purchasing an additional 7,615 shares during the last quarter. Finally, FSM Wealth Advisors LLC grew its holdings in shares of AstraZeneca by 3.2% during the third quarter. FSM Wealth Advisors LLC now owns 6,138 shares of the company’s stock valued at $478,000 after purchasing an additional 188 shares during the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Erste Group Bank raised AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. TD Cowen increased their price objective on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Finally, Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $89.75.

AstraZeneca Stock Performance

Shares of NASDAQ AZN opened at $63.85 on Thursday. The stock has a fifty day moving average price of $78.45 and a two-hundred day moving average price of $78.75. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.89. The firm has a market cap of $197.97 billion, a P/E ratio of 30.85, a PEG ratio of 1.32 and a beta of 0.47. AstraZeneca PLC has a 1 year low of $60.47 and a 1 year high of $87.68.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.